ArticleScience progress
Effect of deoxyribonuclease I therapy on free circulating DNA level and gene methylation profile changes in patients with endometriosis: Proof of concept and preliminary data.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveEndometriosis is a systemic chronic disease with serious effects on various aspects of female health and wellbeing that has been associated with a significant increase in free circulating DNA (CfDNA) and gene methylation profile changes. Endometriosis is considered a worldwide health problem, affecting approximately 10-12% of women of reproductive age. It is defined as an estrogen-dependent syndrome associated with severe pain and a distinct epigenetic signature. The purpose of this study was to evaluate the effect of deoxyribonuclease (DNase) I therapy on these anomalies.MethodsThis study is a proof-of-concept investigation presenting preliminary data from sixteen patients with endometriosis who were evaluated during infertility consultations. CfDNA extraction, quantification and methylation status tests were performed using commercial kits. DNase I was administered subcutaneously every 2 days for one month, and the pre-treatment and post-treatment CfDNA levels and methylation status, along with the degree of patient discomfort, were compared.ResultsDNase I therapy was associated with a decrease in the overall CfDNA level. Targeted methylation profiles showed exploratory changes in several genes, presented descriptively because no paired inferential reanalysis was performed. Moreover, most patients (15/16) reported a reduction in pain, an improvement in their ability to assume professional activity and fewer sexual function difficulties.ConclusionsThis proof-of-concept study suggests that DNase I therapy may be associated with decreased CfDNA levels and changes in methylation profiles. Patient-reported improvements in pain and quality of life were observed, but they cannot be causally attributed to treatment in the absence of a placebo-controlled design. Further research into the potential use of DNase-based medicine for endometriosis patients involving more participants is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.